The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 09, 2024
Filed:
Mar. 08, 2021
Applicant:
Agios Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
Francesco G. Salituro, Marlborough, MA (US);
Jeffrey O. Saunders, Lincoln, MA (US);
Shunqi Yan, Irvine, CA (US);
Assignee:
Agios Pharmaceutical, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 407/12 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); A61K 31/497 (2006.01); A61K 31/5513 (2006.01); A61K 31/4164 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 35/00 (2006.01); C07D 215/36 (2006.01); C07D 215/40 (2006.01); C07D 239/42 (2006.01); C07D 241/20 (2006.01); C07D 243/08 (2006.01); C07D 271/12 (2006.01); C07D 277/64 (2006.01); C07D 277/68 (2006.01); C07D 319/18 (2006.01); C07D 295/192 (2006.01);
U.S. Cl.
CPC ...
C07D 215/36 (2013.01); A61K 31/497 (2013.01); A61K 31/5513 (2013.01); C07D 215/40 (2013.01); C07D 239/42 (2013.01); C07D 241/20 (2013.01); C07D 243/08 (2013.01); C07D 271/12 (2013.01); C07D 277/64 (2013.01); C07D 277/68 (2013.01); C07D 295/192 (2013.01); C07D 319/18 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 407/12 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); Y02P 20/582 (2015.11);
Abstract
Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.